[Discussion] the compounding gap was a symptom, not a solution
the compounding gap was a symptom, not a solution. It is the sort of thing everyone half-believes and nobody writes down.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
a 503B has to register and report, so there is a paper trail to ask for
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
the pharmacy and the prescriber are two separate questions
the shortage list is the whole legal hinge and people skip it
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
Who is the prescriber, and are they the same organisation as the pharmacy?
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Did they name the facility?
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
shortage status changes and the whole arrangement changes with it
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Was there potency testing on the finished preparation, or only on the starting material?
salt forms are the recurring argument and the answer is boring
salt forms are the recurring argument and the answer is boring
burned_once_twice is right about the concentration trap. It breaks arithmetic that has been reliable for months.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
- 1Push back: "compounded is fine because a pharmacy made it" skips every…9 comments in this branch · started by u/niels_roos
- 2Not convinced. You are comparing a compounded concentration with a branded…7 comments in this branch · started by u/jonas_eriksen